Because at least for EPP, they have market exclusivity for many years post approval for following an orphan disease indication. They also have patents over the slow release delivery method for the drug.
Because at least for EPP, they have market exclusivity for many...
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.19 |
Change
0.030(0.21%) |
Mkt cap ! $707.5M | |||
| Open | High | Low | Value | Volume |
| $14.20 | $14.24 | $14.10 | $237.1K | 16.71K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 141 | $14.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.19 | 131 | 10 |
View Market Depth
| Last trade - 11.05am 15/08/2024 (20 minute delay) ? |
| CUV (ASX) Chart |